ReviewBMJ open respiratory research2020
Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK.
Review in BMJ open respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Metabolomics and Artificial Intelligence (AI) assisted metabolomics in the diagnosis of non-tuberculous mycobacterial infections: progress and challenges.New microbes and new infections · 2026Review
- Enhanced In Vitro Stability of Bedaquiline with Ascorbic Acid and Pyruvate During Long-Term Incubation inAntibiotics (Basel, Switzerland) · 2026Article
- AI-assisted differentiation of nontuberculous mycobacterial pulmonary disease from colonization: a multi-center study.Insights into imaging · 2025Article
- [Factors influencing health-related quality of life among patients with non-tuberculous mycobacterial pulmonary disease in South Korea: a cross-sectional survey study].Journal of Korean biological nursing science · 2025Article
- Nontuberculous mycobacteria remodel lung microbiota in cystic fibrosis-associated respiratory infections.Microbiology spectrum · 2025Article
- Nontuberculous Mycobacterial Lung Disease Management in Belgium: A Longitudinal Pharmacy Database Study.Drugs - real world outcomes · 2025Article
- Biological characterization and genomic analysis of the newly discovered mycobacteriophage WST1.BMC microbiology · 2025Article
- Creation of a macrolide antibiotic against non-tuberculousScience advances · 2025Article
- Article
- Supporting Patients with Nontuberculous Mycobacterial Pulmonary Disease: Ensuring Best Practice in UK Healthcare Settings.Pharmacy (Basel, Switzerland) · 2024Review
- Non-tuberculous mycobacterial pulmonary infection presenting in a patient with unilateral pulmonary artery agenesis.BMJ case reports · 2024Article
- Evaluation of mycobacteria infection prevalence and optimization of the identification process in North Sardinia, Italy.Microbiology spectrum · 2024Article
- Non-tuberculous mycobacterial pulmonary disease (NTM-PD): Epidemiology, diagnosis and multidisciplinary management.Clinical medicine (London, England) · 2024Review
- The problem of Mycobacterium abscessus complex: multi-drug resistance, bacteriophage susceptibility and potential healthcare transmission.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Article
- Best Practices for the Management of Patients with Non-Tuberculous Mycobacterial Pulmonary Disease According to a German Nationwide Analysis of Expert Centers.Healthcare (Basel, Switzerland) · 2023Article
- Eliciting Patient Insights on the Burden of Nontuberculous Mycobacterial Lung Disease (NTM-LD) and Healthcare Gaps in Germany Through Qualitative Semi-structured Interviews.Advances in therapy · 2023Article
- Changing Incidence and Characteristics of Nontuberculous Mycobacterial Infections in Scotland and Comparison WithOpen forum infectious diseases · 2023Article
- Article
- Genomic Analysis of Mycobacterium abscessus Complex Isolates from Patients with Pulmonary Infection in China.Microbiology spectrum · 2022Article
- Impacts of Nontuberculous Mycobacteria Isolates in Non-cystic Fibrosis Bronchiectasis: A 16-Year Cohort Study in Taiwan.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A rising number of non-tuberculous mycobacterial (NTM) isolates are being identified in UK clinical practice. There are many uncertainties around the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD), including its epidemiology, diagnosis, treatment and prevention. Regional variations in how patients with NTM-PD are managed reflects the lack of standardised pathways in the UK. Service optimisation and multidisciplinary working can improve the quality of care for patients with NTM-PD, including (1) better identification of patients at risk of NTM-PD and modification of risk factors where applicable; (2) standardisation of reference laboratory testing to offer clinicians access to accurate and prompt information on NTM species and drug sensitivities; (3) development of recognised specialist NTM nursing care; (4) standardisation of NTM-PD imaging strategies for monitoring of treatment and disease progression; (5) establishment of a hub-and-spoke model of care, including clear referral and management pathways, dedicated NTM-PD multidisciplinary teams, and long-term patient follow-up; (6) formation of clinical networks to link experts who manage diseases associated with NTM; (7) enabling patients to access relevant support groups that can provide information and support for their condition; and (8) development of NTM research groups to allow patient participation in clinical trials and to facilitate professional education.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.